1382. Acid-Fast Bacilli Testing Trends at 43 In- and Outpatient Facilities and Nontuberculous Mycobacterial Pulmonary Isolation Rate, United States, 2009–2015

Yi Ling Lai, MPH1; Emily Ricotta, PhD, ScM1; Kenneth Olivier, MD, MPH2; Samer S. Kaddri, MD, MS1; D. Rebecca Prevote, PhD3; National Institutes of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland; 1National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland; 2NIH Clinical Center, Bethesda, Maryland

Session: 153. Mycobacteria
Friday, October 4, 2019: 12:15 PM

Background. The prevalence of nontuberculous mycobacterial pulmonary disease (NTM PD) is increasing in the United States and globally. The reasons for this increase are not clear but could be related to both gained awareness leading to increased mycobacterial testing, or to a true NTM PD increase. To further examine the role of testing rates in the observed increase, we studied trends in Acid-Fast Bacteria (AFB) testing and NTM isolation positivity using a large Electronic Health Record (EHR) dataset in the United States.

Methods. Using the Cerner Health Facts EHR dataset, we extracted microbiologic, demographic, and clinical data for patient encounters (inpatient or outpatient), with ≥2 orders for AFB respiratory cultures. The analysis was limited to the 43 facilities reporting consistently for the period 2009–2015. A patient with at least one AFB test considered considered (AFB) and a patient with at least one pathogenic NTM respiratory isolate was considered positive. Trends in AFB testing and NTM positivity were estimated using log-linked Poisson regression (P < 0.05).

Results. From 2009 through 2015, of 14.8 million patients, 65,010 had 142,315 AFB tests, averaging 2.2 AFB tests/patient, for an overall testing prevalence of 0.43%; the annual testing prevalence remained unchanged during the study period (P = 0.44) (Figure 1). Of the 65,010 patients with AFB tests, 3,942 (6.1%) had ≥1 NTM-positive culture, 3,094 (78%) had M. abscessus/chelonae species, for an overall pulmonary NTM isolation prevalence of 2.7/10,000 patients represented in Cerner Health Facts dataset. Of the patients that had at least one pathogenic NTM, 3,094 (78%) had M. avium complex, and 265 (7%) had M. abscessus/chelonae (Figure 2). Among patients with at least 1 NTM-positive culture, 138 patients had concomitant growth of M. tuberculosis.

Conclusion. Increases in NTM PD are not explained by increases in AFB testing, with significant rates of NTM PD even in patients with low AFB testing rates. Increases in NTM PD are not explained by increases in AFB testing, with significant rates of NTM PD even in patients with low AFB testing rates. Increases in NTM PD are not explained by increases in AFB testing, with significant rates of NTM PD even in patients with low AFB testing rates.

Disclosures. All authors: No reported disclosures.

1384. Mycobacterium marinum Infection: 21 Years of Experience at a Tertiary-Care Hospital

Natalia E. Castillo Almeida, MD1; Pooja Gurram, MBBS1; Ornab Abu Saleh, MBBS2; 1Mayo Clinic, Rochester, Rochester, Minnesota; 2Mayo Clinic, Rochester, Minnesota

Session: 153. Mycobacteria
Friday, October 4, 2019: 12:15 PM

Background. Mycobacterium marinum is a slow-growing, non-tuberculous mycobacterium responsible for skin and soft-tissue infections (SSTIs), tenosynovitis, and osteomyelitis (OM). We conducted a retrospective study describing the risk, clinical course, and outcome of M. marinum infection.

Methods. Adult patients with culture-confirmed M. marinum infections were identified from the microbiology laboratory at Mayo Clinic, Rochester from January 1998 to December 2018. M. marinum infection was defined as uncomplicated (limited to SST) and complicated (tenosynovitis, OM, or disseminated).

Results. Forty-six cases of culture-confirmed infection with M. marinum were included (Table 1). Only 16 cases (35%) reported a water exposure and 22 (48%) involved finger and/or hand trauma. The median time to diagnosis was 3.6 months. Most patients (76%) presented with uncomplicated M. marinum infection with skin lesions mainly localized in the upper limb (Table 2). Quantiferon and PPD were positive in 4 (8%) and 2 (4%) cases, respectively. Granulomatous inflammation and positive special stains were noted in 34 (74%) and 11 (24%) cases, respectively. Cases with complicated M. marinum infection had a longer duration of symptoms and length of treatment (P < 0.05) (Table 3). Prior to diagnosis, 63% of patients received at least one antibiotic for bacterial SSTIs. More than 50% of the patients diagnosed with M. marinum received a one drug regimen and 8% did not initiate therapy. Median treatment duration was 4.4 months. Twenty-six cases (56%) had susceptibilities performed and treatment modifications were made in 10 cases (38%). From the patients that started therapy, 73% completed therapy and 33% were lost to follow up. Cured was achieved in 87% of cases that completed therapy, 2 cases (6%) had a recurrence, and only one patient with active malignancy had a positive blood culture and died. Twelve (44%) and 10 cases (37%) were cured with one and two-drug regimens, respectively.

Conclusion. Patients with M. marinum infection present as an uncomplicated infection in the upper limb. Classical exposure was only suspected in a third of the cases. Patients with complicated M. marinum infection had a prolonged duration of symptoms and lengthy treatment. Most patients were successfully treated with one and two-drug regimens.

Disclosures. All authors: No reported disclosures.

1385. Everolimus is Associated with an Increased Risk of Tuberculosis in Solid-Organ Transplant Recipients

Hsin-Yun Chang, MD1; Arvind Cheng, MBBChir2; So-Meng Wang, MD2; Meng-Kun Tsai, MD2; Yih-Shang Chen, Surgery2; Sheng-Shen Wang, Surgery2; Cheng-Maw Ho, MD1; Rey-Heng Hu, MD2; Hao-Hsun Hsu, MD2; Chi-Tai Fang, MD PhD3; Yee-Chun Chen, MD, PhD3; Shan-Chwen Chang, MD, PhD3; National Taiwan University Hospital, Taipei, Taiwan (Republic of China); 2Fu Jen Catholic University Hospital, New Taipei City, New Taipei, Taiwan (Republic of China); 3National Taiwan University Hospital, Taipei, Taiwan (Republic of China)

Session: 153. Mycobacteria
Friday, October 4, 2019: 12:15 PM

Background. Tuberculosis (TB) is an important post-transplant infection. Everolimus has been documented to reduce the risk of cytomegalovirus infection in transplant recipients, but its impact on other infections is less known. The present study aimed to test the hypothesis that immunosuppressive regimens on TB risk in solid-organ transplant (SOT) recipients via a matched case–control study.

Methods. From May 2005 to December 2018, SOT recipients with TB were retrospectively identified, and those without TB undergoing transplantation at the same university hospital were selected as controls. Controls and cases were matched by age (±5 years), transplant type and year (±5 years) at a ratio of 4:1. Conditional logistic regression was used to analyze the risk factors of TB.

Results. TB developed in 30 SOT recipients (13 kidney, 7 heart, 6 liver, and 4 lung) after a mean duration of 1,601 days after transplantation, with predominant lung involvement (87%). The diagnosis was made by culture in 70% and pathology in 17%. Rafamycins-based regimens were used in 27 cases, and 4 developed rejection without graft failure. A total of 106 controls were selected. At the time of TB diagnosis, cases were more likely to use everolimus than controls (27% vs. 11%, P < 0.05), but no significant differences were observed in the use of tacrolimus, cyclosporin, sirolimus, prednisolone, or mycophenolate mofetil. The median duration of everolimus use was 585 and 698 days in 8 cases and 12 controls, respectively. Multivariable analysis showed that everolimus use (adjust odds ratio [aOR] 22.3, 95% confidence interval [CI] 2.5–203.0) and hemodialysis (OR 19.6, 95% CI 1.3–287.1) were independently associated with TB.

Conclusion. TB is more likely to develop in SOT recipients on everolimus and hemodialysis. Further studies to confirm our findings are warranted, and TB risk assessment should be performed for those receiving everolimus and hemodialysis.

Disclosures. All authors: No reported disclosures.


### Table 2. Clinical presentation and laboratory findings at initial presentation

| Clinical presentation | N = 46 |
|-----------------------|--------|
| Upper extremity       | 44 (95) |
| Redness (%)           | 28 (61) |
| Pain (%)              | 25 (54.3) |
| Abscess (%)           | 9 (19.6) |
| Skin manifestations* (%) | 34 (74) |
| Symphalgies (%)       | 12 (26.1) |
| Constitutional (%)    | 13 (29) |
| Constitutional symptoms (%) | 4 (8.7) |
| Time to evaluation (days), median | 20 (4-366) |

### Laboratory findings

| WBC, mean ± SD | 6.14 (2.23) |
| Platelets, mean ± SD | 252 (94.5) |
| Creatinine, mean ± SD | 1.06 |
| ESR, median (range) | 5.0 (60) |
| CRP, median (range) | 3.0 (3.190) |
| Time of positive culture, mean ± SD | 28.2 ± 15.3 |

*Skin manifestations include nodules, papules and plaques

### Table 3. Complicated versus non-complicated

| Uncomplicated n = 35 | Complicated n = 11 | P value |
|----------------------|-------------------|---------|
| Gender               |                   |         |
| Male (%)             | 19                | 9       | 0.160 |
| Female (%)           | 16                | 2       |       |
| Immunosuppression    |                   |         |
| IMI                  |                   |         |
| MAB, mean ± SD       | 6.14              | 6.42    | 0.731 |
| Platelets, mean ± SD | 253.1             | 251.3   | 0.959 |
| ESR, median          | 5                 | 9       | 0.825 |
| CRP, median          | 2.4               | 3       | 0.417 |
| Duration of symptoms |                   |         |
| prior to diagnosis (months, median) | 2.9 | 4.7 | 0.026 |
| Number of drugs used |                   |         |
| mean                | 1                 | 2       |       |
| Length of treatment (months, median) | 3.6 | 5.7 | 0.031 |

**Disclosures.** All authors: No reported disclosures.

1386. Mechanism-Based, In Vitro Inhibition of Mycobacterium abscessus: Assessing β-Lactam Therapy

Khalid M. Dousa, MD; Sebastian G. Kurz, MD; Christopher R. Bethel, MS; Melissa D. Barnes, PhD; Magdalena A. Taracila, MS; Suresh Selvaraju, MD/PhD; Michael R. Jacobs, MD/PhD; Barry Kreiswirth, PhD; Shannon H. Kasperbauer, MD; Charles L. Daley, MD; Robert A. Bonomo, MD;
1Case Western Reserve University, Cleveland Heights, Ohio; 2Mount Sinai National Jewish Health Respiratory Institute, New York City, New York; 3Research Service, Louis Stokes Veterans Affairs Medical Center, Cleveland, Ohio; 4MetroHealth Medical Center, Cleveland, Ohio; 5Center for Discovery and Innovation, Newark, New Jersey; 6Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, Colorado; 7Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio

**Session:** Mycobacteria

**Friday, October 4, 2019: 12:15 PM**

**Background.** M. abscessus (Mab) is an emerging pathogen, a highly drug-resistant rapidly-growing nontuberculous mycobacteria. Mab L, D transpeptidases (LdtL, D), D,D carboxypeptidase and BlaMab (1–2) is an emerging pathogen, a highly drug-resistant rapidly-growing nontuberculous mycobacteria. Mab L, D transpeptidases (LdtL, D), D,D carboxypeptidase and BlaMab (1–2) is an emerging pathogen, a highly drug-resistant rapidly-growing nontuberculous mycobacteria. Mab L, D transpeptidases (LdtL, D), D,D carboxypeptidase and BlaMab (1–2) is an emerging pathogen, a highly drug-resistant rapidly-growing nontuberculous mycobacteria. Mab L, D transpeptidases (LdtL, D), D,D carboxypeptidase and BlaMab (1–2) is an emerging pathogen, a highly drug-resistant rapidly-growing nontuberculous mycobacteria. Mab L, D transpeptidases (LdtL, D), D,D carboxypeptidase and BlaMab (1–2)

**Methods.** Minimum inhibitory concentrations (MICs) of TAR and IMI with or without AVI and REL and a TAR-IMI combination with and without REL were determined using microdilution. Approximately 5 x 10^4 colony-forming units (CFU) per milliliter were inoculated into Middlebrook 7H9 broth supplemented with 10% (vol/vol) oleic albumin dextrose catalase and 0.05% (vol/vol) Tween 80. AVI or REL were added at fixed concentration of 4 µg/mL to serial dilutions of TAR or IMI. For the determination with two diazabicyclooctanone β-lactamase inhibitors (BLI), relebactam (REL) and aztreonam (AVI), 153. Mycobacteria

**Disclosures.** All authors: No reported disclosures.

1386. Reduction in Expected Survival Associated with Nontuberculous Mycobacterial Pulmonary Infection

Ahmad Mourad, MD; Arthur W. Baker, MD, MPH; Jason E. Stout, MD, MHS; 1Duke University Medical Center, Durham, North Carolina; 2School of Medicine, Duke University, Durham, North Carolina; 3Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, North Carolina

**Session:** Mycobacteria

**Friday, October 4, 2019: 12:15 PM**

**Background.** Nontuberculous mycobacteria (NTM) are emerging agents of pulmonary disease, estimated to affect >80,000 people in the United States. While the spectrum of pulmonary NTM severity is broad, some published series report 5-year mortality of up to 40%.

**Methods.** We conducted a retrospective cohort study to examine mortality of patients with positive respiratory cultures for NTM in the Duke Health System from January 1, 1996 to June 30, 2015, compared with the expected mortality in the US population among a cohort with the same demographic composition. We included patients with 2+ positive NTM respiratory cultures, or 1 positive culture plus an associated ICD diagnosis. Patients with disseminated NTM, HIV, cystic fibrosis, and solid-organ or hematopoietic cell transplants were excluded, as were isolates of Mycobacterium gordonae. Five specific comorbidities (cancer, chronic obstructive pulmonary disease, stroke, chronic renal failure, myocardial infarction) were assessed with ICD codes. Survival was measured from the date of first positive NTM culture and censored as of 6/30/2015.

**Results.** We identified 653 patients who met the case definition. 451 (69%) were female; 548 (84%) were Caucasian, and the median age was 69 years (IQR 59–76). 544 (83.3%) patients had only Mycobacterium avium complex (MAC) isolates in cultures; 39 (6%) had only M. abscessus; 33 (5%) had both MAC and M. abscessus; 37 (5.7%) had...